{
  "headers": [
    "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA"
  ],
  "rows": [
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "RESEARCH QUESTIONS"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "Current FDA enforcement on supplements? FTC actions on electrolyte brands? Defensible vs risky claims? Best-in-class compliant brands?"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "CURRENT STATE"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "[What does this domain look like right now? Key players, standard practices, consensus view.]"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "BEST IN CLASS"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "[Who does this exceptionally well? What specifically makes them good? What can we steal?]"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "WHERE THE INDUSTRY IS WRONG"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "[Conventional wisdom that's wrong or outdated. Assumptions that don't hold.]"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "OUR CONTRARIAN TAKE"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "[What we believe that most would disagree with. Why we're right.]"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "IMPLICATIONS FOR IONWAVE"
    },
    {
      "INDUSTRY PERSPECTIVES — M7: REGULATORY & FDA": "[What we do differently. What we steal. What we avoid.]"
    }
  ],
  "row_count": 12,
  "sheet_name": "IP-M7",
  "sheet_index": 249
}